Back to results
US 11,883,428 B2Granted
Enteric aerobization therapy
AssigneeLpoxy Therapeutics, Inc.
InventorLarry D. Sutton
Life of this patent
Estimating the term…
Abstract
Agents, kits, and methods that utilize oxygenation to prevent and/or treat infections caused by anaerobic microorganisms are provided. The agents, kits, and methods according to several embodiments utilize oxygenation in the intestinal lumen to prevent and/or treat infections caused by anaerobic bacteria. The agents, kits, and methods can be utilized to prevent and/or treat anaerobic bacterial infections of the intestinal lumen by enteric aerobization therapy.
Claims14
An oral formulation in solid form for treating an intestinal anaerobic bacterial infection, comprising:
- an agent, a catalyst, a first controlled release coating encasing the agent, a second controlled release coating encasing the catalyst and the encased agent, a porous membrane that encapsulates the catalyst and the encased agent, and an enteric coating surrounding the oral formulation,
- wherein the agent comprises sodium percarbonate or carbamide peroxide,
- wherein the catalyst comprises catalase,
- wherein the catalase controls the rate of conversion of the agent to oxygen,
- wherein the porous membrane comprises at least two or more layers made of one or more of:
- cellulose propionates, cellulose acetate butyrates, cellulose acetate acetoacetate, cellulose chloroacetate, cellulose acetate furoate, dimethoxyethyl cellulose acetate with a functional pore size that prevents a majority of the catalyst from diffusing across the membrane,
- wherein the functional pore size is smaller than an actual pore size,
- wherein the pore size is sufficient to allow water to diffuse across any portion of the membrane to contact the agent and to allow oxygen to diffuse across any portion of the membrane into an intestine of the subject, wherein when orally administered to a subject, the agent provides 2-5% of said oxygen in at least a portion of the intestine for 24 hours or more to create an aerobic environment in the intestine sufficient to inhibit growth of a population of anaerobic bacteria that caused an anaerobic bacterial infection in the intestine,
- and wherein the oral formulation is in a solid form as a pill or a capsule.
6 more elements
An oral formulation in solid form for treating an intestinal anaerobic bacterial infection, comprising:
- an agent, a catalyst, a first controlled release coating encasing the agent, a second controlled release coating encasing the catalyst and the encased agent, a porous membrane that encapsulates the catalyst and the agent, and an enteric coating surrounding the oral formulation,
- wherein the catalyst controls the rate of conversion of the agent to oxygen,
- wherein the porous membrane comprises at least two polymeric layers having a functional pore size that is smaller than an actual pore size, wherein the actual pore size is between 10 and 100 kilodaltons, which thereby prevents a majority of the catalyst from diffusing across the membrane,
- wherein the pore size is sufficient to allow water to diffuse across any portion of the membrane to contact the agent and to allow oxygen to diffuse across any portion of the membrane into an intestine of the subject,
- wherein, when orally administered to a subject, the agent provides 2-5% of said oxygen in at least a portion of the intestine for 24 hours or more to create an aerobic environment in the intestine sufficient to inhibit growth of a population of anaerobic bacteria that are capable of causing an anaerobic bacterial infection in the intestine, and
- wherein the population of anaerobic bacteria comprises Clostridioides difficile;
- and
- wherein the oral formulation is in a solid form.
5 more elements
An oral formulation in solid form for treating an intestinal anaerobic bacterial infection, comprising:
- at least one agent that delivers oxygen or acts as a source of oxygen in an intestine when administered to a subject,
- wherein said at least one agent is in a solid form,
- a catalyst, a first controlled release coating encasing the agent, a second controlled release coating encasing the catalyst and the encased agent, a porous cellulose membrane encapsulating the catalyst and the agent,
- wherein the porous cellulose membrane comprises two or more layers of cellulose having a functional pore size smaller than an actual pore size, wherein the actual pore size restricts diffusion of molecules greater than 10 kilodaltons, which thereby prevents a majority of the catalyst from diffusing across the membrane,
- wherein the pore size is sufficient to allow water to diffuse across any portion of the membrane to contact the agent and to allow oxygen to diffuse across any portion of the membrane into an intestine of the subject, and
- an enteric coating surrounding the oral formulation, and
- wherein the oxygen is capable of creating an aerobic environment in the intestine sufficient to treat the anaerobic bacterial infection by reducing a population of anaerobic bacteria.
4 more elements
Dependencies are inferred from the claim text.